Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2010

View Archived Issues

Scientists design PIE-12-trimer that specifically inhibits HIV entry into host cells

Phase I data presented on hypnotic agent GF-015535-00

Interim phase I/II data suggest safety of everolimus in advanced HCC

Novartis reports on clinical development of LDE-225

BI-10773 improves glycemic control in large study in type 2 diabetes

Phico Therapeutics details phase I tolerability of PT1.2

Immatics raises funds to advance cancer vaccine portfolio

NasVax begins phase IIa trial of oral anti-CD3 immunotherapy

University of Kansas claims new HSP 90 inhibitors

Pro-Pharmaceuticals and Numoda collaborate on phase III Davanat trial

FDA and EMA to review vandetanib for advanced medullary thyroid cancer

AnGes receives fast track status for Collategene in critical limb ischemia

Santaris Pharma to initiate phase IIa trial of miravirsen in hepatitis C

Dynavax begins phase Ib study of its universal flu vaccine candidate

GSK to use biomarker from OncoMethylome in immunotherapy program

S*BIO obtains funding to support clinical programs

DiagnoCure files PMA application with FDA for Progensa PCA3 assay

RXi and EyeGate Pharma collaborate on ocular drug delivery system

Abbott and Reata to codevelop bardoxolone methyl for CKD

New dual GLP-1/glucagon receptor agonists described

FDA orphan drug status for darinaparsin in peripheral T-cell lymphoma

Vifor and Kissei Pharma partner to develop and market PA-21 in Japan

European orphan status granted to rFVIIIFc in hemophilia A

OP Bio Factory and Nagoya University disclose new beta-NGF enhancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....